The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma

The recent introduction of monoclonal antibodies (MoAbs), with several cellular targets, such as CD-38 (daratumumab and isatuximab) and SLAM F7 (elotuzumab), differently combined with other classes of agents, has significantly extended the outcomes of patients with multiple myeloma (MM) in different...

Descripción completa

Detalles Bibliográficos
Autores principales: Zamagni, Elena, Tacchetti, Paola, Deias, Paola, Patriarca, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764080/
https://www.ncbi.nlm.nih.gov/pubmed/33321731
http://dx.doi.org/10.3390/ph13120451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764080/
https://www.ncbi.nlm.nih.gov/pubmed/33321731
http://dx.doi.org/10.3390/ph13120451

Ejemplares similares